1982 American Board of Obstetrics and Gynecology (Recertified 2003)
1983 Subspecialty Certificate, Gynecologic Oncology (Recertified 2003)

Education and Training

Undergraduate
Sept 1966 - 1970
Harvard College
Cambridge, Massachusetts
BA in Biology

Graduate
Sept 1971 - May 1975
Case Western Reserve University School of Medicine
Cleveland, Ohio
MD

Postgraduate
July 1975 - June 1978
Assistant Resident, Obstetrics and Gynecology
Duke University Medical Center
Durham, North Carolina

July 1978 - June 1979
Chief Resident, Obstetrics and Gynecology
Duke University Medical Center
Durham, North Carolina

July 1979 - June 1981
Fellow, Gynecologic Oncology
Duke University Medical Center
Durham, North Carolina

Appointments and Positions

1980-1984
Assistant Professor of Obstetrics and Gynecology
Duke University Medical Center
Durham, North Carolina

1982-1984
Co-Director
Southeastern Trophoblastic Disease Center
Duke University Medical Center
Durham, North Carolina

1984
Associate Professor of Obstetrics/Gynecology
Duke University Medical Center
Durham, North Carolina

1984-1986
Associate Professor of Obstetrics/Gynecology
University of Illinois at Chicago School of Medicine
Chicago, Illinois

1984-1985
Director of Gynecologic Oncology
University of Illinois at Chicago School of Medicine
Chicago, Illinois

1985-1986
Director of Gynecology and Gynecologic Oncology
University of Illinois at Chicago School of Medicine
Chicago, Illinois

1987-2005
Professor and Director of Obstetrics and Gynecology
Duke University Medical Center
Durham, North Carolina

1993-2005
James M. Ingram Professor of Gynecologic Oncology
Duke University Medical Center
Durham, North Carolina

2005-Present
Robert A. Ross Professor of Obstetrics and Gynecology
University of North Carolina School of Medicine
Chapel Hill, North Carolina

2005-Present
Chairman, Department of Obstetrics and Gynecology
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Membership in Professional
& Scientific Societies

A. National/International

• 1982 Fellow, American College of Obstetricians
--and Gynecologists
• 1982 Society of Gynecologic Oncologists
• 1982 Gynecologic Oncology Group
• 1985 American Medical Association
• 1985 Central Association of Obstetricians
--and Gynecologists
• 1987 American Society of Clinical Oncologists
• 1988 International Gynecologic Cancer Society
• 1989 Fellow, American College of Surgeons
• 1993 Fellow, American Gynecological
--and Obstetrical Society
• 1994 Society of Pelvic Surgeons

B. Regional

• 1979 Piedmont Obstetrical and Gynecological Society
• 1979 Bayard Carter Society of Obstetricians
--and Gynecologists
• 1985-1987 Chicago Medical Society
• 1985-1987 Illinois Cancer Council
• 1985-1987 Illinois State Medical Society
• 1985 Central Association of Obstetricians and
--Gynecologists
• 1985-1987 Chicago Association of Gynecologic
--Oncologists
• 1986 Chicago Gynecological Society
• 1987 North Carolina Medical Society
• 1987 North Carolina Obstetrical and
--Gynecological Society
• 1988 Mid-Atlantic Gynecologic Oncology Society
• 1988 Southern Obstetrical & Gynecological Seminar

Committees

American Gynecologic & Obstetrical Society
• 1996-1999 Member, Fellowship Committee
--2000 Member, Nominating Committee
--(AGOS Foundation)

American College of Obstetricians & Gynecologists
• 1977 Junior Fellow Section Program Chairman
• 1978 Junior Fellow Section Co-Chairman
• 1979 Junior Fellow Section Chairman
• 1987-1991 Committee on Technical Bulletins
• 1993-1997 Committee on Gynecologic Practice
• 1993-1997 Chairman, Committee on Gynecologic
--Oncology Practice
• 1993-1997 ACOG Liaison Representative to the

Society of Gynecologic Oncologists
• 2001 Editorial Board: Precis, Oncology Society
--of Gynecologic Oncologists
• 1993-1994 Ad hoc Council Member
• 1994-1998 Council Member
• 1993-1994 Ad hoc Committee on Clinical Practice
--Policy Development
• 1994-1997 Member, Committee on Clinical Practice
• 1994-1995 Chairman, 1995 Program Committee
• 1994-present Member, Education Committee
• 2003 Nominating Committee

American Board of Obstetrics and Gynecology
• 1988-present Board Examiner: Obstetrics and
--Gynecology
• 1991 Board Examiner: Gynecologic Oncology
• 1987-present Director of Gynecologic Oncology
--Fellowship Program (Duke Univ)
• 2001 Board Examiner: Gynecologic Oncology

Gynecologic Oncology Group
• 1991-present Principal Investigator
--Duke University
• 1982-1985, 1987-1991 Co-Principal Investigator
--Duke University Grant
• 1982-1990 Gynecologic Management Committee
• 1990-1998 Ovarian Cancer Committee

North Carolina Department of Environment,
Health, and Natural Resources
• 1990-1992 Member, Task Force on Cervical Cancer
--Chairman, Subcommittee on Impact of Appropriate
--Follow-up Care

North Carolina OB/GYN Society
• 1991-1993 Chairman, Gynecology Committee
• 1991-1993 Member, Professional Activities Committee

Mid Atlantic Gynecologic Oncology Society
• 2000 Program Chairman (Annual Meeting)
• 2002 President-Elect
• 2003 President and Program Chairman
--(Annual Meeting)

Honors
• 1979 Junior Fellow First Prize Paper
--ACOG District IV
• 1980 American Cancer Society Clinical Fellow
• 1981 Junior Fellow First Prize Paper
--ACOG District IV
• 1981 Clinical Research Paper, Second Place
--ACOG Annual Clinical Meeting
• 1982 Donald F. Richardson Memorial Prize Paper
--Best research paper presented by a Junior Fellow
--at a District ACOG Meeting
• 1981-1984 Junior Faculty Clinical Fellowship
--American Cancer Society
• 1985 Clinical Research Prize Paper - ACOG
--District VI Meeting
• 1991 Invited Panel Participant:
--Consensus Meeting on the Prevention of Thromboembolism --Windsor, England
• 2001 America’s Top Doctors
• 2002 ACOG Roy Pitkin/Elsevier Award:
--One of top four papers published annually
--in Obstetrics and Gynecolog
• 2004 Invited Panel Member, International Consensus- - - - - Conference of the Prevention of Venous Thromboembolism

Recent Publications
Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, Long HJ.  Intraperitoneal Radioactive Phosphorous (32P) versus observation folowing negative Second-Look Laparotomy for Stage III Ovarian Carcinoma: A Randomized Trial of the Gynecologic Oncology Group.  J Clin Oncol 2003; 21: 2849-2855

Clarke-Pearson DL, Maxwell GL, Synan I, Dodge R, McClelland C.  Risk factors which predispose patients to thromboembolism despite prophylaxis with external pneumatic compression.  Obstet Gynecol 2003; 101:157-163.

Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL.  Prevention of Venous Thrombosis in Postoperative Gynecologic Oncology Patients:  A Prospective Randomized Trial Comparing Pneumatic Calf Compression and Low Molecular Weight Heparin (dalteparin)   Obstet Gynecol  2001; 98: 989-995

Maxwell GL, Synan I, Hayes R, Clarke-Pearson DL. Preference and Compliance in Thromboembolism Prophylaxis for Gynecologic Oncology Patients.  Obstet Gynecol.  2002, 100: 451

Jones EL, Samulski TV, Dewhirst MW, Secord AA, Berchuck A, Clarke-Pearson DL, Havrilesky LJ, Soper J, Prosnitz LR.  A Pilot Phase II Trial of Concurrent Radiotherapy, Chemotherapy, and Hyperthermia for Locally Advanced Cervical Carcinoma.  Cancer. 2003;  98:277-282.

Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH.    Secondary Surgical Cytoreduction for Advanced Stage Ovarian Carcinoma with Suboptimal Residual Disease.   N Engl J Med.  2004; 351: 2489-97.

Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, Douglass EC.  A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol. 2003; 91: 318-25

Dainty L, Maxwell GL, Clarke-Pearson DL, Myers ER. Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery.  Gynecol Oncol 2004; 93: 366-73.

Secord AA, Jones EL, Hahn CA, Petros WP, Yu D, Havrilesky LJ, Soper JT, Berchuck A, Spasojevic I, Clarke-Pearson DL, Prosnitz LR, Dewhirst MW.  Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.  Int J Hyperthermia 2005; 21: 333-47

Spriggs D, Clarke-Pearson DL.  A Phase III Randomized Trial of Cisplatin and Paclitaxel Administered by Either 24 hour or 96 Hour Infusion in Patients with Selected Stage III or Stage IV Epithelial Ovarian Cancer (GOG 162)  (Submitted  Am J Clin Oncol) 2004

Greer B, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson DL, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen RN, Copeland LJ.  Implications of second-look laparotomy in the context of optimally resected Stage III Ovarian Cancer:  A non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group Study.   J Clin Oncol. 2005; 99: 71-9.

Walker JL, Armstrong D, Huang H, Fowler J, Webster K, Burger R, Clarke-Pearson D. Intraperitoneal Catheter Outcomes in a Phase III Trial of Intravenous vs. Intraperitoneal Chemotherapy in Optimal Stage III Ovarian and Primary Peritoneal Cancer. A Gynecologic Oncology Group Study.  Gynecol Oncol (Accepted 11/05)

Soper JT, Lutman CV, Havrilesky L J, Cragun JM, Secord, AA, Caligaert B, Berchuck A, Clarke-Pearson DL.    Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology
(Accepted, Gyn Oncol)

Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT Clarke-Pearson DL, Berchuck A.  Resection of lymph node metastases influences survival in stage IIIC endometrial cancer.  Gynecol Oncol. 2005;

Soper JT, Havrilesky LJ, Secord AA, Berchuck A, Clarke-Pearson DL.  Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery.  Int J Gynecol Cancer. 2005; 15: 542-8.

Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A.  Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.  J Clin Oncol   2005; 23: 3668-75.

Soper JT, Secord AA, Havrilesky LJ, Berchuck A, Clarke-Pearson DL.  Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison fo flap-relatred morbidity.  Gynecol Oncol. 2005; 97: 596-601.

Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, Long HJ. Intraperitoneal Radioactive Phosphorous (32P) versus observation folowing negative Second-Look Laparotomy for Stage III Ovarian Carcinoma: A Randomized Trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 2849-2855

Clarke-Pearson DL, Maxwell GL, Synan I, Dodge R, McClelland C. Risk factors which predispose patients to thromboembolism despite prophylaxis with external pneumatic compression. Obstet Gynecol 2003; 101:157-163.

Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Prevention of Venous Thrombosis in Postoperative Gynecologic Oncology Patients: A Prospective Randomized Trial Comparing Pneumatic Calf Compression and Low Molecular Weight Heparin (dalteparin) Obstet Gynecol 2001; 98: 989-995

Maxwell GL, Synan I, Hayes R, Clarke-Pearson DL. Preference and Compliance in Thromboembolism Prophylaxis for Gynecologic Oncology Patients. Obstet Gynecol. 2002, 100: 451

Jones EL, Samulski TV, Dewhirst MW, Secord AA, Berchuck A, Clarke-Pearson DL, Havrilesky LJ, Soper J, Prosnitz LR. A Pilot Phase II Trial of Concurrent Radiotherapy, Chemotherapy, and Hyperthermia for Locally Advanced Cervical Carcinoma. Cancer. 2003; 98:277-282.

Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH. Secondary Surgical Cytoreduction for Advanced Stage Ovarian Carcinoma with Suboptimal Residual Disease. N Engl J Med. 2004; 351: 2489-97.

Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, Douglass EC. A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol. 2003; 91: 318-25

Dainty L, Maxwell GL, Clarke-Pearson DL, Myers ER. Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery. Gynecol Oncol 2004; 93: 366-73.

Secord AA, Jones EL, Hahn CA, Petros WP, Yu D, Havrilesky LJ, Soper JT, Berchuck A, Spasojevic I, Clarke-Pearson DL, Prosnitz LR, Dewhirst MW. Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. Int J Hyperthermia 2005; 21: 333-47

Spriggs D, Clarke-Pearson DL. A Phase III Randomized Trial of Cisplatin and Paclitaxel Administered by Either 24 hour or 96 Hour Infusion in Patients with Selected Stage III or Stage IV Epithelial Ovarian Cancer (GOG 162) (Submitted Am J Clin Oncol) 2004

Greer B, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson DL, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen RN, Copeland LJ. Implications of second-look laparotomy in the context of optimally resected Stage III Ovarian Cancer: A non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group Study. J Clin Oncol. 2005; 99: 71-9.

Walker JL, Armstrong D, Huang H, Fowler J, Webster K, Burger R, Clarke-Pearson D. Intraperitoneal Catheter Outcomes in a Phase III Trial of Intravenous vs. Intraperitoneal Chemotherapy in Optimal Stage III Ovarian and Primary Peritoneal Cancer. A Gynecologic Oncology Group Study. Gynecol Oncol (Accepted 11/05)

Soper JT, Lutman CV, Havrilesky L J, Cragun JM, Secord, AA, Caligaert B, Berchuck A, Clarke-Pearson DL. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology (Accepted, Gyn Oncol)

Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT Clarke-Pearson DL, Berchuck A. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol. 2005;

Soper JT, Havrilesky LJ, Secord AA, Berchuck A, Clarke-Pearson DL. Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery. Int J Gynecol Cancer. 2005; 15: 542-8.

Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005; 23: 3668-75.

Soper JT, Secord AA, Havrilesky LJ, Berchuck A, Clarke-Pearson DL. Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison fo flap-relatred morbidity. Gynecol Oncol. 2005; 97: 596-601.

Lutman CV, Havrilesky LJ, Cragun JM, Secord A, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT.  Pelvic lymph node count is an important prognostic variable for FIGO Stage I and II endometrial carcinoma with high risk histology.  Gynecol Oncol (accepted 2006)